A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis

被引:102
作者
Gottlieb, A. B. [1 ]
Langley, R. G. [2 ]
Strober, B. E. [3 ]
Papp, K. A. [4 ]
Klekotka, P. [5 ]
Creamer, K. [5 ]
Thompson, E. H. Z. [5 ]
Hooper, M. [5 ]
Kricorian, G. [5 ]
机构
[1] Tufts Med Ctr, Boston, MA USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Univ Connecticut, Sch Med, Farmington, CT USA
[4] Prob Med Res, Waterloo, ON, Canada
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
LONG-TERM SAFETY; RHEUMATOID-ARTHRITIS; COMBINATION ETANERCEPT; VS; METHOTREXATE; OPEN-LABEL; CONTROLLED-TRIAL; 50; MG; EFFICACY; MONOTHERAPY; THERAPY;
D O I
10.1111/j.1365-2133.2012.11015.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis. Objectives To evaluate etanercept plus methotrexate vs. etanercept monotherapy in patients with moderate to severe plaque psoriasis who had not failed prior methotrexate or tumour necrosis factor-inhibitor therapy. Methods Patients received etanercept 50 mg twice weekly for 12 weeks followed by 50 mg once weekly for 12 weeks and were randomized 1 : 1 to receive methotrexate (7.5-15 mg weekly) or placebo. The primary endpoint was the proportion of patients achieving >= 75% improvement in Psoriasis Area and Severity Index (PASI 75) at week 24. Results In total, 239 patients were enrolled in each arm. PASI 75 was significantly higher at week 24 for the combination therapy group compared with the monotherapy group (77.3% vs. 60.3%; P < 0 0001). Other PASI improvement scores at week 12 [PASI 75, 70.2% vs. 54.3% (P = 0.01); PASI 50, 92.4% vs. 83.8% (P = 0.01); and PASI 90, 34.0% vs. 23.1% (P = 0.03)] showed similar results as did week 24 PASI 50 (91.6% vs. 84.6%; P = 0.01) and PASI 90 (53.8% vs. 34 2%; P = 0 01). Significantly more patients receiving combination therapy than monotherapy had static Physician's Global Assessment of clear/almost clear at week 12 (65.5% vs. 47.0%; P = 0.01) and week 24 (71.8% vs. 54.3%; P = 0.01). Adverse events (AEs) were reported in 74.9% and 59.8% of combination therapy and monotherapy groups, respectively; three serious AEs were reported in each arm. Conclusions Combination therapy with etanercept plus methotrexate had acceptable tolerability and increased efficacy compared with etanercept monotherapy in patients with moderate to severe psoriasis.
引用
收藏
页码:649 / 657
页数:9
相关论文
共 45 条
[1]   Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate [J].
Amital, Howard ;
Arnson, Yoav ;
Chodick, Gabriel ;
Shalev, Varda .
RHEUMATOLOGY, 2009, 48 (09) :1107-1110
[2]  
[Anonymous], 1999, COMM TOX CRIT VERS 2
[3]   Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: a multicentre prospective randomized controlled clinical trial [J].
Arani, S. Fallah ;
Neumann, H. ;
Hop, W. C. J. ;
Thio, H. B. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 164 (04) :855-861
[4]   Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) [J].
Barker, J. ;
Hoffmann, M. ;
Wozel, G. ;
Ortonne, J. -P. ;
Zheng, H. ;
van Hoogstraten, H. ;
Reich, K. .
BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (05) :1109-1117
[5]   Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic [J].
Barker, J. ;
Horn, E. J. ;
Lebwohl, M. ;
Warren, R. B. ;
Nast, A. ;
Rosenberg, W. ;
Smith, C. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2011, 25 (07) :758-764
[6]   Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort [J].
Dalaker, M. ;
Bonesronning, J. H. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (03) :277-282
[7]   Etanercept combined with methotrexate for high-need psoriasis [J].
Driessen, R. J. B. ;
van de Kerkhof, P. C. M. ;
de Jong, E. M. G. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 159 (02) :460-463
[8]   Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial [J].
Emery, Paul ;
Breedveld, Ferdinand C. ;
Hall, Stephen ;
Durez, Patrick ;
Chang, David J. ;
Robertson, Deborah ;
Singh, Amitabh ;
Pedersen, Ronald D. ;
Koenig, Andrew S. ;
Freundlich, Bruce .
LANCET, 2008, 372 (9636) :375-382
[9]   Two-Year Clinical and Radiographic Results With Combination Etanercept-Methotrexate Therapy Versus Monotherapy in Early Rheumatoid Arthritis [J].
Emery, Paul ;
Breedveld, Ferdinand ;
van der Heijde, Desiree ;
Ferraccioli, Gianfranco ;
Dougados, Maxime ;
Robertson, Deborah ;
Pedersen, Ronald ;
Koenig, Andrew S. ;
Freundlich, Bruce .
ARTHRITIS AND RHEUMATISM, 2010, 62 (03) :674-682
[10]  
Enbrel&REG